112 related articles for article (PubMed ID: 35489389)
1. An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1-7 rescue of the diabetic phenotype.
Gheblawi M; de Oliveira AA; Williams VR; John R; Grant MB; Scholey JW; Oudit GY
J Mol Cell Cardiol; 2022 Aug; 169():10-12. PubMed ID: 35489389
[No Abstract] [Full Text] [Related]
2. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow.
Mordwinkin NM; Meeks CJ; Jadhav SS; Espinoza T; Roda N; diZerega GS; Louie SG; Rodgers KE
Endocrinology; 2012 May; 153(5):2189-97. PubMed ID: 22434085
[TBL] [Abstract][Full Text] [Related]
3. Targeted overexpression of endothelial nitric oxide synthase in endothelial cells improves cerebrovascular reactivity in Ins2Akita-type-1 diabetic mice.
Chandra SB; Mohan S; Ford BM; Huang L; Janardhanan P; Deo KS; Cong L; Muir ER; Duong TQ
J Cereb Blood Flow Metab; 2016 Jun; 36(6):1135-42. PubMed ID: 26661212
[TBL] [Abstract][Full Text] [Related]
4. Peroxidasin promotes diabetic vascular endothelial dysfunction induced by advanced glycation end products via NOX2/HOCl/Akt/eNOS pathway.
Jing Cao ; Zhang G; Liu Z; Xu Q; Li C; Cheng G; Shi R
Redox Biol; 2021 Sep; 45():102031. PubMed ID: 34116361
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase.
Chen J; Zhang J; Shaik NF; Yi B; Wei X; Yang XF; Naik UP; Summer R; Yan G; Xu X; Sun J
J Biol Chem; 2019 Dec; 294(51):19565-19576. PubMed ID: 31719145
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver.
Herath CB; Mak K; Burrell LM; Angus PW
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G99-108. PubMed ID: 23086915
[TBL] [Abstract][Full Text] [Related]
7. An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia.
Fraga-Silva RA; Costa-Fraga FP; Savergnini SQ; De Sousa FB; Montecucco F; da Silva D; Sinisterra RD; Mach F; Stergiopulos N; da Silva RF; Santos RA
J Sex Med; 2013 Oct; 10(10):2430-42. PubMed ID: 23890028
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II.
Kossmann S; Hu H; Steven S; Schönfelder T; Fraccarollo D; Mikhed Y; Brähler M; Knorr M; Brandt M; Karbach SH; Becker C; Oelze M; Bauersachs J; Widder J; Münzel T; Daiber A; Wenzel P
J Biol Chem; 2014 Oct; 289(40):27540-50. PubMed ID: 25143378
[TBL] [Abstract][Full Text] [Related]
9. Induction of KLF2 by Exercise Activates eNOS to Improve Vasodilatation in Diabetic Mice.
Luo JY; Cheng CK; Gou L; He L; Zhao L; Zhang Y; Wang L; Lau CW; Xu A; Chen AF; Huang Y
Diabetes; 2023 Sep; 72(9):1330-1342. PubMed ID: 37347764
[TBL] [Abstract][Full Text] [Related]
10. Ablation of angiotensin type 2 receptor prevents endothelial nitric oxide synthase glutathionylation and nitration in ischaemic abductor muscle of diabetic mice.
Robillard S; Mercier C; Breton V; Paquin-Veillette J; Guay A; Lizotte F; Geraldes P
Diab Vasc Dis Res; 2020; 17(1):1479164119883978. PubMed ID: 31726870
[TBL] [Abstract][Full Text] [Related]
11. Endothelial function is disturbed in a hypertensive diabetic animal model of HFpEF: Moderate continuous vs. high intensity interval training.
Schmederer Z; Rolim N; Bowen TS; Linke A; Wisloff U; Adams V;
Int J Cardiol; 2018 Dec; 273():147-154. PubMed ID: 30193792
[TBL] [Abstract][Full Text] [Related]
12. Bone Morphogenic Protein 4 Mediates NOX1-Dependent eNOS Uncoupling, Endothelial Dysfunction, and COX2 Induction in Type 2 Diabetes Mellitus.
Youn JY; Zhou J; Cai H
Mol Endocrinol; 2015 Aug; 29(8):1123-33. PubMed ID: 26121233
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.
Kanetsuna Y; Takahashi K; Nagata M; Gannon MA; Breyer MD; Harris RC; Takahashi T
Am J Pathol; 2007 May; 170(5):1473-84. PubMed ID: 17456755
[TBL] [Abstract][Full Text] [Related]
14. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice.
Molnar J; Yu S; Mzhavia N; Pau C; Chereshnev I; Dansky HM
Circ Res; 2005 Jun; 96(11):1178-84. PubMed ID: 15879311
[TBL] [Abstract][Full Text] [Related]
15. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.
Matsumoto S; Shimabukuro M; Fukuda D; Soeki T; Yamakawa K; Masuzaki H; Sata M
Cardiovasc Diabetol; 2014 Jan; 13():30. PubMed ID: 24485356
[TBL] [Abstract][Full Text] [Related]
16. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-(1-7) improves diabetes mellitus-induced erectile dysfunction in rats by regulating nitric oxide synthase levels.
Xu Y; Zhang F; Li C; Hao H; Hao Y
Peptides; 2022 May; 151():170765. PubMed ID: 35181349
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor.
Olson S; Oeckler R; Li X; Du L; Traganos F; Zhao X; Burke-Wolin T
Am J Physiol Lung Cell Mol Physiol; 2004 Sep; 287(3):L559-68. PubMed ID: 15155270
[TBL] [Abstract][Full Text] [Related]
19. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats.
Zhang Y; Lu J; Shi J; Lin X; Dong J; Zhang S; Liu Y; Tong Q
Neuropeptides; 2008; 42(5-6):593-600. PubMed ID: 18990443
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
Meakin PJ; Coull BM; Tuharska Z; McCaffery C; Akoumianakis I; Antoniades C; Brown J; Griffin KJ; Platt F; Ozber CH; Yuldasheva NY; Makava N; Skromna A; Prescott A; McNeilly AD; Siddiqui M; Palmer CN; Khan F; Ashford ML
J Clin Invest; 2020 Aug; 130(8):4104-4117. PubMed ID: 32407295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
